» Articles » PMID: 19471094

Angiotensin II Induces Inflammatory Response Partly Via Toll-like Receptor 4-dependent Signaling Pathway in Vascular Smooth Muscle Cells

Overview
Date 2009 May 28
PMID 19471094
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Angiotensin (Ang II) plays an important role in atherosclerosis through proinflammatory effect. Toll-like receptor 4 (TLR4) may mediate inflammatory response. It is unknown whether TLR4 mediates the proinflammatory effect of Ang II. Thus, we observed the role and signaling pathway of TLR4 in Ang II-induced inflammation in rat vascular smooth muscle cells (VSMCs). Ang II and LPS stimulated TNF-alpha secretion and inhibited 6-keto-PGF(1alpha ) production, upregulated MMP-9 and downregulated PPARgamma and PPARalphain rat VSMCs. Ang II also distinctly upregulated TLR4 expression in the cells. Pretreatment of the cells with anti-TLR4 antibody prior to Ang II stimulation significantly diminished the effects of Ang II. These suggest that Ang II stimulates VSMCs to produce inflammation through regulation of the proinflammatory and the antiinflammtory factors via TLR4-dependent mechanism. The further investigations showed that AT1 receptor antagonist losartan or ERK1/2 inhibitor PD098059 inhibited Ang II-induced TLR4 expression, TLR4 inhibitor prevented Ang II- induced IP-10 expression, anti-IP-10 antibody partly abolished Ang II- induced PKC increase, and PKC inhibitor chelerythrine suppressed Ang II- induced NF-kappaB expression. These demonstrate that TLR4-mediated proinflammatory effect of Ang II in VSMCs involves AT1/ERK1/2/TLR4/IP-10/ PKC/NF-kappaB pathway. Our results provide the evidence that Ang II induces inflammatory response involved in pathogenesis of atherosclerosis partly via TLR4- dependent signaling pathway in VSMCs.

Citing Articles

Imperatorin's Effect on Myocardial Infarction Based on Network Pharmacology and Molecular Docking.

Zhang R, Wang P, Jin Y, Xie Q, Xiao P Cardiovasc Ther. 2025; 2025():7551459.

PMID: 39834616 PMC: 11745561. DOI: 10.1155/cdr/7551459.


Pharmacological Mechanisms of Cryptotanshinone: Recent Advances in Cardiovascular, Cancer, and Neurological Disease Applications.

Zheng Z, Ke L, Ye S, Shi P, Yao H Drug Des Devel Ther. 2024; 18:6031-6060.

PMID: 39703195 PMC: 11658958. DOI: 10.2147/DDDT.S494555.


The Complex Connection Between Myocardial Dysfunction and Cancer Beyond Cardiotoxicity: Shared Risk Factors and Common Molecular Pathways.

Molnar A, Birges K, Surman A, Merkely B Int J Mol Sci. 2024; 25(23).

PMID: 39684895 PMC: 11642109. DOI: 10.3390/ijms252313185.


Current Mouse Models of Intracranial Aneurysms: Analysis of Pharmacological Agents Used to Induce Aneurysms and Their Impact on Translational Research.

Khan D, Li X, Hashimoto T, Tanikawa R, Niemela M, Lawton M J Am Heart Assoc. 2024; 13(3):e031811.

PMID: 38258667 PMC: 11056163. DOI: 10.1161/JAHA.123.031811.


Immunomodulation and immunopharmacology in heart failure.

Markousis-Mavrogenis G, Baumhove L, Al-Mubarak A, Aboumsallem J, Bomer N, Voors A Nat Rev Cardiol. 2023; 21(2):119-149.

PMID: 37709934 DOI: 10.1038/s41569-023-00919-6.